- Home
- VANI vs PROK Comparison
VANI vs PROK Comparison
Compare VANI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- PROK
- Stock Information
- Founded
- VANI 1998
- PROK 2015
- Country
- VANI United States
- PROK United States
- Employees
- VANI N/A
- PROK N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VANI Health Care
- PROK Health Care
- Exchange
- VANI Nasdaq
- PROK Nasdaq
- Market Cap
- VANI 88.3M
- PROK 85.5M
- IPO Year
- VANI 2014
- PROK N/A
- Fundamental
- Price
- VANI $1.33
- PROK $2.82
- Analyst Decision
- VANI Strong Buy
- PROK Buy
- Analyst Count
- VANI 1
- PROK 5
- Target Price
- VANI $4.00
- PROK $6.25
- AVG Volume (30 Days)
- VANI 121.4K
- PROK 37.5M
- Earning Date
- VANI 08-12-2025
- PROK 08-12-2025
- Dividend Yield
- VANI N/A
- PROK N/A
- EPS Growth
- VANI N/A
- PROK N/A
- EPS
- VANI N/A
- PROK N/A
- Revenue
- VANI N/A
- PROK $306,000.00
- Revenue This Year
- VANI N/A
- PROK $105.79
- Revenue Next Year
- VANI N/A
- PROK N/A
- P/E Ratio
- VANI N/A
- PROK N/A
- Revenue Growth
- VANI N/A
- PROK N/A
- 52 Week Low
- VANI $0.91
- PROK $0.46
- 52 Week High
- VANI $1.80
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- VANI 40.85
- PROK 53.07
- Support Level
- VANI $1.53
- PROK $2.56
- Resistance Level
- VANI $1.64
- PROK $3.04
- Average True Range (ATR)
- VANI 0.09
- PROK 0.43
- MACD
- VANI -0.03
- PROK -0.16
- Stochastic Oscillator
- VANI 7.44
- PROK 14.94
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.